Navigation Links
DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial

San Diego, CA (PRWEB) April 09, 2013

The drug safety advocates at are alerting of updated legal news on the site for patients who have taken the diabetes drug Actos. Trial continues against the maker of the drug for a man alleging it caused his terminal bladder cancer***.

DrugRisks is designed to improve the safety of those taking popular prescription drugs like Actos by providing the latest warnings, recalls, studies and legal news. Visitors can determine if other patients are experiencing similar side effects and decide if they need legal advice.

The FDA and European Medicines Agency* have warned that taking Actos for longer than one year may be associated with an increased risk of bladder cancer. Regulators in France and Germany have also banned it from being prescribed**.

The resource center discovered as many as 3,000 patients in the U.S. have filed an Actos lawsuit against Takeda Pharmaceuticals over allegations their drug caused bladder cancer***. The first trial began last month in California for Jack Cooper, a grandfather who is terminally ill from the disease***.

Now DrugRisks notes an article from Law360 on March 26, 2013 which quotes the testimony in this case of Dr. Norm D. Smith, an assistant professor of urology and surgery at the University of Chicago, that Actos was the “most substantial causative factor” of Mr. Cooper’s advanced cancer****.

Lawyers continue to help those diagnosed with bladder cancer after taking Actos file claims. Anyone affected is urged to contact the DrugRisks Center or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of drug injury litigation against large pharmaceutical companies, DrugRisks only recommends lawyers and law firms who have already handled Actos lawsuits.

Visit today for more information on Actos bladder cancer research, side effects and litigation news, or to speak with a lawyer.

*; an_pha_detail_000033.jsp&mid=WC0b01ac058001d126
***; Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court (Los Angeles).
****Claran McEvoy, "Actos 'Most Substantial" Factor in Man's Cancer, Doc Testifies," March 26, 2013, Law360

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisks Adds Study Showing Pradaxa Viral Infection Risk
2. DrugRisks Stryker Recall Update: Company Warns Investors as Patients Alleging Injury Ask to Send Lawsuits to Federal Court
3. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
4. DrugRisks Adds New Pradaxa Study Alert As Lawsuits Increase
5. DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
6. Johnson & Johnson Ethicon Transvaginal Mesh Lawsuits Update: Resource4thePeople Reports Judge Schedules More Trials for This Summer
7. DrugRisk Update: Mirena Maker Asks to Keep Lawsuits With Local Court, Judge
8. DrugRisk Update: Bayer Adds Gallbladder Claims to Yaz Settlements
9. Skechers Injury Lawsuit Update: Richard W. Schulte, Partner with Wright & Schulte LLC, Appointed to Plaintiffs’ Steering Committee in California Skechers Toning Shoes Litigation
10. DrugRisk Update: New Pradaxa Study Questions FDA Safety Conclusion
11. Hip Safety Center Update: Patients Ask to Send Stryker Hip Lawsuits to Federal Court
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... 26, 2015 , ... The Catalent Applied Drug Delivery Institute ... integrate dose form selection in early phase drug development. The first of these ... bringing together the UK’s emerging life sciences companies, corporate partners, and investors, at ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/26/2015)... Aliso Viejo, CA (PRWEB) , ... November 26, ... ... X users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. ... custom style options. These classically-influenced trailer titles work with any font, giving users ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
(Date:11/26/2015)... 26, 2015 --> ... SyMRI to find optimal contrast weighting of MRI for ... has signed a research agreement with SyntheticMR in order to ... SyMRI, it is possible to generate multiple contrast images from ... patient has left, thus making it possible to both fine ...
(Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
Breaking Medicine Technology: